FibroGen, Inc.
http://www.fibrogen.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From FibroGen, Inc.
Seagen Digs Deep For Lava’s Bispecific Antibody
Deal Snapshot: The Dutch biotech planned to move its preclinical candidate, the EGFR-targeting LAVA-1223, into the clinic later this year. Seagen has shown interest in business development as Merck merger talks have quieted down.
GSK Confident Its ‘Last Drug Standing’ In Anemia Class Can Gain US Panel Backing
GSK could have the US market to itself if it can convince the expert panel of daprodustat’s safety, as rivals have fallen by the wayside.
Will 2022 Be US FDA’s Year Of ‘No’? Approval Rate For Novel Agents Plunged In First Half
With 19 novel approvals and 14 complete response letters in the first half of 2022, the year is shaping up to be a turnabout from the big approval counts and rare CRLs of the recent approvals boom years.
$55m For Akebia As Otsuka Confirms Vadadustat Exit
Japanese firm extricates itself from international deals for oral anemia drug, leaving Akebia potentially needing to find a new partner to progress development and commercialization.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Medical Devices
- Biomaterials
- Other Names / Subsidiaries
-
- FibroGen China Anemia Holdings Ltd.
- FibroGen (China) Medical Technology Development Co., Ltd.
- FibroGen Europe Oy
- FibroGen International (Cayman) Limited
- FibroGen International (Hong Kong) Limited
- Skin Sciences, Inc.